Anti-Mullerian hormone (AMH) in the adolescent girls presenting with hyperandrogenism

Bogdanova P.S.; Kareva M.A.; Iarovaia I.S.; Zlotnikova O.A.; Il'in A.V.; Dedov I.I.

doi:https://doi.org/

Bogdanova P.S.

Institut detskoĭ éndokrinologii Éndokrinologicheskogo nauchnogo tsentra, Moskva

Kareva M.A.

Institut detskoĭ éndokrinologii Éndokrinologicheskogo nauchnogo tsentra, Moskva

Iarovaia I.S.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Zlotnikova O.A.

FGBU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Il'in A.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Dedov I.I.

Endocrinology Research Centre

Anti-Mullerian hormone (AMH) in the adolescent girls presenting with hyperandrogenism

Authors:

Bogdanova P.S., Kareva M.A., Iarovaia I.S., Zlotnikova O.A., Il'in A.V., Dedov I.I.

More about the authors

Journal: Problems of Endocrinology. 2012;58(1): 9‑16

Read: 3412 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bogdanova PS, Kareva MA, Iarovaia IS, Zlotnikova OA, Il'in AV, Dedov II. Anti-Mullerian hormone (AMH) in the adolescent girls presenting with hyperandrogenism. Problems of Endocrinology. 2012;58(1):9‑16. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Prediction of menstrual-ovarian cycle disorders in adolescent girls based on the study of genetic markers. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):12-18

Features of the course of induced pregnancy during the transfer of a thawed embryo in women with polycystic ovary syndrome. Russian Journal of Human Reproduction. 2025;(1):54-62

Abstract:

Anti-Mullerian hormone (AMH) is known to be a reliable marker of disturbances in folliculogenesis. The present paper is designed to report the results of AMH determination in 57 adolescent girls differing in the clinical course of hyperandogenism depending on the severity of its symptoms and androgen levels in the peripheral blood.

Keywords:

anti-Mullerian hormone hyperandrogenism

polycystic ovary syndrome

non-classical form of congenital adrenal cortical dysfunction

adolescent girls

Authors:

Bogdanova P.S.

Institut detskoĭ éndokrinologii Éndokrinologicheskogo nauchnogo tsentra, Moskva

Kareva M.A.

Institut detskoĭ éndokrinologii Éndokrinologicheskogo nauchnogo tsentra, Moskva

Iarovaia I.S.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Zlotnikova O.A.

FGBU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Il'in A.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Dedov I.I.

Endocrinology Research Centre

Close metadata

References:

Azziz R., Carmina E., Dewailly D. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete taskforse report. Fertil Steril 2009; 91: 456-488.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2007; 19: 41-47.
Kumar A., Woods K., Bartolucci A., Azziz R. Prevalence of Adrenal Androgen Excess in Patients with PCOS: Discussion. Clin Endocrinol 2005; 62: 6: 644-649.
Ibanez L., DiMartino-Nardi J., Potau N. Premature adrenarche - normal variant or forerunner of adult disease? Endocrine Reviews 2000; 21: 671-696.
Bern V., Picard J.Y., Dien T., Laur L., Nath J. Production of Anti-Mullerian Hormone: Another Homology between Sertoli and Granulosa Cells. Endocrinology 1984; 114: 1315-1320.
La Marca A., Broekmans F.J., Volpe A., Fauser B.C., Macklon N.S. Anti-Mullerian hormone (AMH): what do we still need to know? Human Reproduction 2009; 24: 2264-2275.
Piltonen T., Morin-Papunen L., Koivunen R., Perheentupa A., Ruokonen A., Tapanainen J.S. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Human Reprod 2005; 20: 1820-1826.
Catteau-Jonard S., Jamin S.P., Leclerc A., Gonzales J., Dewailly D., di Clemente N. Anti-Mullerian Hormone, Its Receptor, FSH Receptor, and Androgen Receptor Genes Are Overexpressed by Granulosa Cells from Stimulated Follicles in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2008; 93: 4456-4461.
Pellatt L., Rise S., Mason H. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010; 39: 5: 825-833.
Nardo L.G., Yates A.P., Roberts S.A., Pemberton P., Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Human Reprod 2009; 24: 2917-2923.
Piouka A., Farmakiotis D., Katsikis I., Macut D., Gerou S., Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Phys Endocrinol Metabol 2009; 296: E238-E243.
Carlsen S.M., Vanky E., Fleming R. Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Human Reprod 2009; 24: 1732-1738.
Jayaprakasan K., Campbell B., Hopkisson J., Johnson I., Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 2010; 93: 3: 855-864.
Laven J., Mulders A., Visser J., Themmen A., de Jong F., Fauser B. Anti-Mullerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive Age. J Clin Endocrinol Metab 2004; 89: 318-323.
Siow Y., Kives S., Hertweck P., Perlman S., Fallat M.E. Serum mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005; 84: 4: 938-944.
Balen A., Laven J., Tan S. Ultrasound assessment of polycystic ovary: international consensus definitions. Human Reprod Update 2003; 9: 6: 505-514.
Deplewski D., Rosenfeld R. Role of Hormones in Pilosebaceous Unit Development. Endocrine Reviews 2000; 21: 4: 363-392.
Stener-Victorin E., Holm G., Labrie F. Are There Any Sensitive and Specific Sex Steroid Markers for Polycystic Ovary Syndrome? J Clin Endocrinol Metab 2010; 95: 2: 810-819.
Legro R.S., Schlaff W.D., Diamond M.P., Coutifaris C., Casson P.R., Brzyski R.G., Christman G.M., Trussell J.C., Krawetz S.A., Snyder P.J., Ohl D., Carson S.A., Steinkampf M.P., Carr B.R., McGovern P.G., Cataldo N.A., Gosman G.G., Nestler J.E., Myers E.R., Santoro N., Eisenberg E., Zhang M., Zhang H. for the Reproductive Medicine Network. Total Testosterone Assays in Women with Polycystic Ovary Syndrome: Precision and Correlation with Hirsutism. J Clin Endocrinol Metab 2010; 95: 5305-5313.
Goncharov N.P., Katsiya G.V. Sovremennye metody opredeleniya testosterona. Vestn reprod zdorov'ya 2008; 1: 31-37.
Rosner W., Vesper H. On behalf of The Endocrine Society the endorsing organizations. Toward Excellence in Testosterone Testing: A Consensus Statement. J Clin Endocrinol Metab 2010; 95: 4542-4548.
Dewailly D., Pigny P., Soudan B., Catteau-Jonard S., Decanter C., Poncelet E., Duhamel A. Reconciling the Definitions of Polycystic Ovary Syndrome: The Ovarian Follicle Number and Serum Anti-M+-llerian Hormone Concentrations Aggregate with the Markers of Hyperandrogenism. J Clin Endocrinol Metab 2010; 95: 4399-4405.